Last reviewed · How we verify
Phenylephrine-ketorolac
Phenylephrine-ketorolac is a combination drug that uses a sympathomimetic vasoconstrictor (phenylephrine) and a nonsteroidal anti-inflammatory agent (ketorolac) to reduce bleeding and inflammation during ophthalmic surgery.
Phenylephrine-ketorolac is a combination drug that uses a sympathomimetic vasoconstrictor (phenylephrine) and a nonsteroidal anti-inflammatory agent (ketorolac) to reduce bleeding and inflammation during ophthalmic surgery. Used for Intraoperative mydriasis and hemostasis during ophthalmic surgery.
At a glance
| Generic name | Phenylephrine-ketorolac |
|---|---|
| Also known as | Omidria |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | Combination sympathomimetic and NSAID |
| Target | Alpha-1 adrenergic receptor (phenylephrine); COX-1/COX-2 (ketorolac) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Phenylephrine acts as an alpha-1 adrenergic agonist that constricts blood vessels in the eye, reducing bleeding and improving surgical visibility. Ketorolac is a potent NSAID that inhibits prostaglandin synthesis, further reducing inflammation and bleeding tendency. Together, they provide hemostasis and anti-inflammatory effects during intraocular procedures.
Approved indications
- Intraoperative mydriasis and hemostasis during ophthalmic surgery
Common side effects
- Corneal edema
- Increased intraocular pressure
- Conjunctival hyperemia
- Anterior chamber inflammation
Key clinical trials
- Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- No Drop Post-Op Cataract Surgery (PHASE4)
- Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery (PHASE4)
- Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study (PHASE3)
- Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain (PHASE4)
- Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenylephrine-ketorolac CI brief — competitive landscape report
- Phenylephrine-ketorolac updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI